PASG, US7027122099

Passage Bio stock pivots as Q3 loss narrows ahead of Remix merger

Published on 11/12/2026 at 03:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Passage Bio stock enters a planned merger with Remix after shareholders approved it. The biotech is winding down gene therapy programs before a fourth-quarter closing.

Passage Bio prepares for corporate transition

Shareholders approved the Remix merger proposals on November 5, with closing still expected in the fourth quarter.
Passage Bio narrowed its third-quarter net loss to 4.7 million USD from 7.7 million USD a year earlier.
Cash stood at 20.2 million USD on September 30, while nine-month operating cash use reached 26.2 million USD.

PASG, US7027122099, Illustration mit AI erstellt.

Passage Bio is preparing for a corporate transition after shareholders approved the proposed merger with Remix Therapeutics on November 5. The transaction is expected to close in the fourth quarter of 2026, subject to remaining conditions, according to Quartr.

Merger approval changes the outlook

The approved proposals include the issuance of Passage Bio shares to Remix securityholders, a reverse stock split in a range from 1-for-2 to 1-for-10, and a planned name change to Remix Therapeutics once the transaction becomes effective. The combined company is also expected to receive approximately 100.0 million USD in gross financing, split between shares and pre-funded warrants on one side and convertible notes on the other.

Existing Passage Bio holders are expected to own about 6 percent of the combined company, while former Remix holders would hold about 65 percent and concurrent financing participants about 29 percent, subject to adjustments. The structure leaves the merger closing and financing completion as key conditions for the next stage.

Loss narrows as programs wind down

Passage Bio reported a third-quarter net loss of 4.7 million USD, compared with 7.7 million USD a year earlier. Operating expenses fell to 4.9 million USD from 8.7 million USD, while nine-month operating expenses declined to 21.5 million USD from 38.1 million USD.

The company is winding down its gene therapy programs and expects research, development and general and administrative costs to decrease as staffing, consulting and facility expenses fall. Merger-related legal and professional costs are expected to rise in the near term.

Liquidity remains a central risk

Cash and cash equivalents totaled 20.2 million USD on September 30, down from 46.3 million USD at the end of 2025. Operating cash use reached 26.2 million USD during the first nine months, and the estimated cash balance at closing is 10.9 million USD.

These figures keep the completion of the merger and its associated financing central to Passage Bio's near-term financial position. The transaction would shift the business toward Remix's RNA-focused therapeutic platform, but the change remains dependent on closing conditions.

Passage Bio's business and position

Passage Bio is a clinical-stage genetic medicines company focused on one-time therapies for neurodegenerative diseases. Its lead product candidate, PBFT02, was designed to raise progranulin levels in conditions including frontotemporal dementia, according to the company's investor overview. The planned merger would move the company away from its legacy gene therapy operations and toward Remix's RNA-targeted development strategy.